News & Updates

Show Multimedia Only

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

20 Jun 2024 by

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

20 Jun 2024

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

20 Jun 2024 by

Patients with AHP who do not achieve an attack-free status after the first 6 months of givosiran treatment can still benefit from further attack reductions and QoL improvements with continued treatment up to 36 months, according to the results from the ENVISION trial presented at EASL 2024

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

20 Jun 2024

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

20 Jun 2024 by

In patients with HRS accompanied by rapidly progressive worsening in kidney function, an interruption of terlipressin dose does not appear to hinder the achievement of HRS reversal, according to a post hoc analysis of data from the CONFIRM study presented at DDW 2024

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

20 Jun 2024

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

20 Jun 2024 by

Treatment with bulevirtide, either 2 or 10 mg, has shown sustained improvement in virologic and biochemical responses in patients with chronic hepatitis delta (CHD), according to the MYR301 study presented at EASL 2024.

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

20 Jun 2024

Physical activity substantially cuts cirrhosis risk in MASLD patients

19 Jun 2024 by

A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Physical activity substantially cuts cirrhosis risk in MASLD patients

19 Jun 2024

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

19 Jun 2024 by

Light-chain (AL) amyloidosis is a progressive, underdiagnosed disease with multiorgan involvement, most notably of the heart, kidneys, and liver. Nearly half of the patients consult ≥4 physicians before receiving correct diagnosis. At the Hong Kong Society of Haematology Annual Scientific Meeting (HKSH ASM) 2024, Professor Morie Gertz of the Mayo Clinic, Minnesota, US, shared insights into establishing an early and accurate diagnosis and discussed the ANDROMEDA trial, which led to the first US FDA–approved treatment – daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd).

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

19 Jun 2024

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

19 Jun 2024 by

Long-term treatment with elafibranor improves biochemical response and itch-related quality of life (QoL) in patients with primary biliary cholangitis (PBC), according to data from the ELATIVE trial presented at EASL 2024.

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

19 Jun 2024

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024 by

In a phase IIb open-label trial, combination therapy with bulevirtide and peginterferon alfa-2a (pegIFNα) yields a synergistic on-treatment effect, with more patients achieving undetectable HDV RNA levels compared to bulevirtide alone.

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

18 Jun 2024

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

17 Jun 2024 by

The latest update of the model for end-stage liver disease (MELD), MELD 3.0, predicts mortality in multiethnic Asian patients hospitalized with cirrhosis with greater accuracy than previous models, according to a study from Singapore.

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

17 Jun 2024

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024 by

Treatment with tirzepatide for 52 weeks resulted in MASH* resolution, with no worsening of fibrosis in patients with MASH and fibrosis in the phase II SYNERGY-NASH trial.

Tirzepatide resolves MASH without worsening fibrosis

11 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

Extending givosiran use may help non–attack-free AHP patients achieve attack-free status

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

HRS reversal feasible in select HRS patients despite terlipressin dose interruption

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Bulevirtide monotherapy sustains virologic, biochemical responses in CHD

Physical activity substantially cuts cirrhosis risk in MASLD patients

Physical activity substantially cuts cirrhosis risk in MASLD patients

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

Early diagnosis and management of AL amyloidosis: An underdiagnosed multiorgan disease

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

Elafibranor improves biochemical response, itch-related QoL in patients with PBC

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

Bulevirtide-pegIFNα combo trumps monotherapy for chronic HDV

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

MELD 3.0 validated as superior mortality predictor in Asians with cirrhosis

Tirzepatide resolves MASH without worsening fibrosis

Tirzepatide resolves MASH without worsening fibrosis